Technical Analysis for RVMD - Revolution Medicines, Inc.
| Grade | Last Price | % Change | Price Change |
|---|---|---|---|
| A | 35.15 | -1.90% | -0.68 |
RVMD closed down 2.69 percent on Thursday, April 18, 2024, on 68 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
Earnings due: May 6
*** please verify all earnings dates ***| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Flat |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Calm After Storm | Range Contraction | -1.90% | |
| NR7 | Range Contraction | -1.90% | |
| NR7-2 | Range Contraction | -1.90% | |
| Wide Bands | Range Expansion | -1.90% | |
| Calm After Storm | Range Contraction | -4.54% | |
| NR7 | Range Contraction | -4.54% | |
| Calm After Storm | Range Contraction | -1.10% | |
| Upper Bollinger Band Walk | Strength | -1.10% | |
| Overbought Stochastic | Strength | -1.10% | |
| Bearish Engulfing | Bearish | -2.55% |
| Alert | Time |
|---|---|
| Down 2 % | 27 minutes ago |
| Down 1% | 38 minutes ago |
| Fell Below 10 DMA | 38 minutes ago |
| 60 Minute Opening Range Breakdown | about 1 hour ago |
| Fell Below Previous Day's Low | about 1 hour ago |
Get this analysis on your stocks daily!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/06/2024
Revolution Medicines, Inc. is a clinical-stage precision oncology company focused on developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Cancer Treatment Pharmacology Signal Transduction mTOR Ras Gtpase Combination Therapy
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Cancer Treatment Pharmacology Signal Transduction mTOR Ras Gtpase Combination Therapy
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 38.73 |
| 52 Week Low | 15.46 |
| Average Volume | 1,561,470 |
| 200-Day Moving Average | 28.19 |
| 50-Day Moving Average | 31.59 |
| 20-Day Moving Average | 33.12 |
| 10-Day Moving Average | 35.06 |
| Average True Range | 1.76 |
| RSI (14) | 60.94 |
| ADX | 32.77 |
| +DI | 32.44 |
| -DI | 11.59 |
| Chandelier Exit (Long, 3 ATRs) | 33.46 |
| Chandelier Exit (Short, 3 ATRs) | 34.82 |
| Upper Bollinger Bands | 38.11 |
| Lower Bollinger Band | 28.13 |
| Percent B (%b) | 0.77 |
| BandWidth | 30.14 |
| MACD Line | 1.48 |
| MACD Signal Line | 1.12 |
| MACD Histogram | 0.3598 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 37.93 | ||||
| Resistance 3 (R3) | 38.15 | 37.67 | 37.58 | ||
| Resistance 2 (R2) | 37.67 | 37.14 | 37.56 | 37.46 | |
| Resistance 1 (R1) | 36.75 | 36.80 | 36.51 | 36.53 | 37.35 |
| Pivot Point | 36.27 | 36.27 | 36.15 | 36.16 | 36.27 |
| Support 1 (S1) | 35.35 | 35.74 | 35.11 | 35.13 | 34.31 |
| Support 2 (S2) | 34.87 | 35.40 | 34.76 | 34.20 | |
| Support 3 (S3) | 33.95 | 34.87 | 34.08 | ||
| Support 4 (S4) | 33.73 |
